Arcus Biosciences Inc (RCUS)
15.50
0.00 (0.00%)
USD |
NYSE |
May 02, 10:50
Arcus Biosciences Enterprise Value: 649.40M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 649.40M |
| April 30, 2024 | 624.87M |
| April 29, 2024 | 661.22M |
| April 26, 2024 | 653.95M |
| April 25, 2024 | 579.44M |
| April 24, 2024 | 643.04M |
| April 23, 2024 | 649.40M |
| April 22, 2024 | 574.90M |
| April 19, 2024 | 566.72M |
| April 18, 2024 | 589.43M |
| April 17, 2024 | 589.43M |
| April 16, 2024 | 683.02M |
| April 15, 2024 | 721.19M |
| April 12, 2024 | 747.54M |
| April 11, 2024 | 812.05M |
| April 10, 2024 | 761.17M |
| April 09, 2024 | 826.59M |
| April 08, 2024 | 782.98M |
| April 05, 2024 | 816.60M |
| April 04, 2024 | 810.24M |
| April 03, 2024 | 848.40M |
| April 02, 2024 | 851.12M |
| April 01, 2024 | 920.18M |
| March 28, 2024 | 956.53M |
| March 27, 2024 | 895.65M |
| Date | Value |
|---|---|
| March 26, 2024 | 753.90M |
| March 25, 2024 | 737.54M |
| March 22, 2024 | 733.91M |
| March 21, 2024 | 807.51M |
| March 20, 2024 | 830.23M |
| March 19, 2024 | 812.96M |
| March 18, 2024 | 805.69M |
| March 15, 2024 | 965.61M |
| March 14, 2024 | 905.64M |
| March 13, 2024 | 971.97M |
| March 12, 2024 | 934.72M |
| March 11, 2024 | 968.34M |
| March 08, 2024 | 875.66M |
| March 07, 2024 | 869.30M |
| March 06, 2024 | 1.000B |
| March 05, 2024 | 947.44M |
| March 04, 2024 | 968.34M |
| March 01, 2024 | 976.52M |
| February 29, 2024 | 979.24M |
| February 28, 2024 | 981.06M |
| February 27, 2024 | 1.075B |
| February 26, 2024 | 1.027B |
| February 23, 2024 | 1.016B |
| February 22, 2024 | 1.028B |
| February 21, 2024 | 732.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
22.18M
Minimum
May 11 2022
2.880B
Maximum
Nov 23 2021
855.97M
Average
684.83M
Median
Nov 12 2020
Enterprise Value Benchmarks
| Gilead Sciences Inc | 76.97B |
| Catalyst Pharmaceuticals Inc | 1.654B |
| Integra Lifesciences Holdings Corp | 3.484B |
| Palatin Technologies Inc | 20.69M |
| Petros Pharmaceuticals Inc | -0.3953M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -81.00M |
| Revenue (Quarterly) | 31.00M |
| Total Expenses (Quarterly) | 122.00M |
| EPS Diluted (Quarterly) | -1.08 |
| Profit Margin (Quarterly) | -261.3% |
| Earnings Yield | -26.77% |
| Normalized Earnings Yield | -26.77 |